| Filed On | Filing |
|---|---|
| 14 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Exhibit 99.1 GLP-131 Phase 1 Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants Week 4 Topline Results October 13, 2026 |
| 22 Sep 2026 | 424B5 |
| 22 Sep 2026 |
8-K: Other Events
On September 22, 2026, Biomea Fusion, Inc. (the “Company”) updated the anticipated timing for topline results from the Company’s ongoing Phase I GLP-131 trial for BMF-650 in obese, otherwise healthy volunteers, which are now expected in ... |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 | 8-K: Financial Statements and Exhibits |
| 12 Jun 2026 |
Form 4: Faust Elizabeth, Director
Granted 196,299 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Aguiar Eric, Director
Granted 196,299 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Ray Sumita, Director
Granted 196,299 Stock Option (Right to Buy) |
| 12 Jun 2026 |
Form 4: Averill Julianne, Director
Granted 173,711 Stock Option (Right to Buy) |
| 11 Jun 2026 | 8-K: Submission of Matters to a Vote of Security Holders |
| 11 May 2026 | 10-Q |
| 11 May 2026 | 8-K: Results of Operations and Financial Condition |
| 28 Apr 2026 | 8-K: Regulation FD Disclosure; Other Events |
| 27 Apr 2026 | ARS |
| 27 Apr 2026 | DEF 14A |
| 03 Apr 2026 |
Form 4: Erdtmann Rainer M, Director
Granted 452,512 Stock Option (Right to Buy) |
| 03 Apr 2026 |
Form 4: Hitchcock Michael J.m., Director
Granted 667,477 Stock Option (Right to Buy) |
| 24 Mar 2026 | 10-K |
| 24 Mar 2026 | 8-K: Results of Operations and Financial Condition |
| 25 Feb 2026 | 8-K: Regulation FD Disclosure |
Loading...
